The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials

安慰剂 抗抑郁药 句号(音乐) 双盲 临床试验 医学 精神科 内科学 替代医学 声学 物理 病理 焦虑
作者
Douglas E. Faries,John H. Heiligenstein,G.D. Tollefson,William Z. Potter
出处
期刊:Journal of Clinical Psychopharmacology [Lippincott Williams & Wilkins]
卷期号:21 (6): 561-568 被引量:74
标识
DOI:10.1097/00004714-200112000-00004
摘要

The 1-week single-blind placebo lead-in has long been a standard in double-blind psychopharmacology clinical trials. Although a lead-in period is often necessary (e.g., to receive laboratory results before randomization), some authors have demonstrated that the standard single-blind placebo lead-in's performance was similar to having a lead-in in which placebo was not administered. The single-blind placebo lead-in did not decrease postrandomization placebo response, nor did it increase drug–placebo differences. To eliminate a higher percentage of placebo responders before randomization and to reduce potential biases in baseline ratings, the authors designed and implemented two depression studies with a double-blind variable placebo lead-in period. In these designs, both the patients and personnel at the investigative sites were blinded to the length of the placebo lead-in period and the start of the active treatment period. Approximately 28% of the patients in the double-blind placebo lead-in studies met criteria to be placebo lead-in responders, as compared with fewer than 10% from two single-blind placebo lead-in studies conducted in a similar time frame. Although all patients continued in the study (including placebo lead-in responders), the primary efficacy analysis prospectively excluded double-blind placebo lead-in responders. Analysis of postrandomization changes revealed that double-blind placebo lead-in responders, even when continuing to receive placebo treatment, maintained their response. At the study endpoint, these placebo lead-in responders had significantly lower severity scores than their counterparts who were not lead-in responders. The prospective removal of lead-in responders thus resulted in an increase in mean endpoint placebo group severity scores. This resulted in an increased drug–placebo treatment difference in one of the two studies but had no effect on the treatment difference in the other study.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LL完成签到,获得积分10
1秒前
美好短靴完成签到,获得积分10
1秒前
2秒前
虚幻代桃完成签到,获得积分10
3秒前
空空伊发布了新的文献求助10
3秒前
3秒前
Nole应助大白采纳,获得10
4秒前
4秒前
星辰大海应助poorpopsingle采纳,获得30
4秒前
香蕉觅云应助cldg采纳,获得10
4秒前
4秒前
5秒前
ZZZ完成签到,获得积分10
5秒前
6秒前
6秒前
晚塬完成签到 ,获得积分10
6秒前
xuan发布了新的文献求助10
7秒前
7秒前
科研通AI6.4应助醉熏的苠采纳,获得10
7秒前
NexusExplorer应助南辰采纳,获得10
8秒前
8秒前
斯文钢笔应助炙热从蕾采纳,获得10
8秒前
9秒前
111发布了新的文献求助10
9秒前
xiaoxiao发布了新的文献求助10
10秒前
ZZZ发布了新的文献求助10
11秒前
11秒前
英姑应助跳跃的若血采纳,获得30
11秒前
12秒前
xiao发布了新的文献求助10
13秒前
菜菜发布了新的文献求助10
14秒前
烟花应助cc采纳,获得10
14秒前
研友_Ze2vV8发布了新的文献求助10
15秒前
16秒前
冯F完成签到,获得积分10
16秒前
16秒前
思源应助renew采纳,获得10
17秒前
隐形曼青应助xuan采纳,获得10
17秒前
courage完成签到,获得积分10
18秒前
秀xiu发布了新的文献求助10
18秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Arthritis and Related Conditions, An Issue of Orthopedic Clinics 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7288397
求助须知:如何正确求助?哪些是违规求助? 8908118
关于积分的说明 18853649
捐赠科研通 6957135
什么是DOI,文献DOI怎么找? 3208896
关于科研通互助平台的介绍 2378670
邀请新用户注册赠送积分活动 2184667